市场见解

Why the BARD1 (ASX:BD1) share price is on the rise today

The BARD1 Life Sciences Ltd (ASX: BD1) share price is climbing today following a postiive update from the company. We take a closer look.
The post Why the BARD1 (ASX:BD1) share price is on the rise today appeared first on The Motley Fool Australia. –

increase in asx medical software share price represented by doctor making excited hands up gesture

The BARD1 Life Sciences Ltd (ASX: BD1) share price is in the green during late morning trade. This comes after the life sciences company announced the launch of its EXO-NET product.

When news broke out, BARD1 shares soared to an intraday high of $2.69. However, some profit-taking has led its shares to fetch for (at the time of writing) $2.57, up 3.6%.

Anticipated EXO-NET launch

Investors are pushing BARD1 shares into positive territory following the company’s latest release.

In a statement to the ASX, BARD1 advised it will launch its EXO-NET product at the virtual International Society of Extracellular Vesicles (ISEV) Annual Meeting. Notably, EXO-NET is the company’s first product based on its molecular NET technology. The ISEV meeting will be held from 18 May to 21 May 2021.

BARD1 stated that EXO-NET is a next-generation exosome isolation and purification tool, available only for research use. The molecular NET product captures exosomes from biological samples such as blood, urine and saliva.

Exosomes are nano-sized vesicles that are released from almost all cell types into surrounding body fluids. These biovesicles contain protein, DNA, and ribonucleic acid (RNA) which shuttle between neighbouring and distant cells, allowing functions like cellular communication. Exosomes have huge clinical and commercial potential in the diagnosis and treatment of numerous diseases.

According to Grand View Research, the global exosome market is expected to reach US$2.3 billion by 2030. This represents a growth rate of 18% per year, highlighting the increasing demand for harnessing exosomes.

The ISEV 2021 virtual meeting will showcase all the latest products in extracellular vesicle science. Industry professionals will gather to collate their thoughts and advance current knowledge for societal and economic benefit.

Management commentary

BARD1 chief scientific officer, Dr Peter French welcomed the upcoming event, saying:

We are very excited to launch EXO-NET to the global exosome research market at the ISEV2021 conference. EXO-NET solves the sample preparation problems encountered using traditional exosome capture methods by providing fast, accurate and scalable capture of exosomes from any liquid sample.

Furthermore, the potential of this technology is largely untapped, as only EXO-NET can be customised for the capture of target exosome sub-populations for a range of commercial diagnostic and therapeutic applications. This is becoming a major focus of exosome research and development.

BARD1 CEO, Dr Leearne Hinch went on to add:

This is a major milestone in BARD1’s commercial development of its Molecular NET technology. The exosome field is rapidly growing across research, diagnostic and therapeutic applications for cancer, inflammatory disease and wound healing. BARD1 intends to position itself as a leader in the exosomes field.

About the BARD1 share price

Over the course of the last 12 months, BARD1 shares have accelerated to more than 220%. However, year-to-date performance has jumped higher to post a gain of almost 280%. It’s worth noting though, since mid-March, the company’s shares have gradually trodden lower.

Based on today’s price, BARD1 commands a market capitalisation of roughly $204 million, with approximately 80 million shares on offer.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the BARD1 (ASX:BD1) share price is on the rise today appeared first on The Motley Fool Australia.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!